Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …

Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

As years progress, we are found more often in a postprandial than a postabsorptive state.
Chrononutrition is an integral part of metabolism, pancreatic function, and hormone …

Dipeptidyl peptidase-4 (DPP-4), also known as the T-cell antigen CD26, is a multi-functional
protein which, besides its catalytic activity, also functions as a binding protein and a ligand …

Tirzepatide is a novel glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …

It is increasingly apparent that not only is a cure for the current worldwide diabetes epidemic
required, but also for its major complications, affecting both small and large blood vessels …

Objective To quantify the overall effects of bariatric surgery compared with non-surgical
treatment for obesity. Design Systematic review and meta-analysis based on a random …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists are established pharmaceutical
therapies for the treatment of type 2 diabetes and obesity. They mimic the action of GLP-1 to …

Glucose levels in blood must be constantly maintained within a tight physiological range to
sustain anabolism. Insulin regulates glucose homeostasis via its effects on glucose …

Background & Aims Insulin resistance and lipotoxicity are pathognomonic in non-alcoholic
steatohepatitis (NASH). Glucagon-like peptide-1 (GLP-1) analogues are licensed for type 2 …